Latest Trials

EudraCT Number: 2004-003809-25 Sponsor Protocol Number: L-9134 Start Date: 2004-12-20
Sponsor Name: Sanofi-Synthelabo Co. Ltd.
Full Title: Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea
Medical condition: A NO-SPA és az ibuprofen kombinációja elfogadott és Magyarországon gyakran használták a nőgyógyászati gyakorlatban sok évvel ezelőtt. A kombináció használatával kapcsolatos súlyos mellékhatásról ne...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: HU (Prematurely Ended)
Trial results: View results
EudraCT Number: 2004-002013-36 Sponsor Protocol Number: ACA-SPAI-03-03 Start Date: 2004-12-17
Sponsor Name: CONCEPCION MORO SERRANO
Full Title: A PROSPECTIVE DOUBLE BLIND AND RANDOMIZED STUDY ON THE EFFECT OF TRANDOLAPRIL, IN MAINTAINING SINUS RHYTHM IN PATIENTS WITH LONG-LASTING PERSISTENT ATRIAL FIBRILLATION. ESTUDIO PROSPECTIVO, DOBLE ...
Medical condition: PACIENTES CON FA PERSISTENTE DE LARGA DURACÍON.
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-001943-31 Sponsor Protocol Number: SEC-2004-001 Start Date: 2004-12-17
Sponsor Name: Sociedad Española de Cardiología
Full Title: ESTUDIO ALEATORIZADO PARA COMPARAR LA EFICACIA Y SEGURIDAD DE LA FIBRINOLISIS O LA ANGIOPLASTIA PRIMARIA COMO TRATAMIENTO INICIAL DE REPERFUSIÓN EN LOS PACIENTES DE EDAD AVANZADA (>/=75 AÑOS) CON I...
Medical condition: Acute Myocardial infarction
Disease: Version SOC Term Classification Code Term Level
M15 10028597 PT
Population Age: Elderly Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2004-001190-25 Sponsor Protocol Number: A6291015 Start Date: 2004-12-17
Sponsor Name: Pfizer Ltd
Full Title: A Double-blind, Proof of Concept Trial of the Use of Pegvisomant to Reduce Urinary Albumin Excretion in Type 1 and Type 2 Diabetic Patients Treated with Angiotensin Convertase Inhibitors/Angiotensi...
Medical condition: Diabetic nephropathy DN (Diabetes mellitus (DM) type I and type II with renal manifestations). MedDRA classification code : 10061835, 10045236 and 10045250 (Version 7.0, Level LLT)
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: LT (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) DK (Completed)
Trial results: View results
EudraCT Number: 2004-000616-70 Sponsor Protocol Number: HMR1964D/3001 Start Date: 2004-12-17
Sponsor Name: Aventis Pharmaceuticals, Inc.
Full Title: Efficacy and safety of insulin glulisine compared with insulin lispro in children and adolescents with type 1 diabetes mellitus: a 26-week, multicenter, open, parallel clinical trial
Medical condition: Type 1 diabetes mellitus
Disease: Version SOC Term Classification Code Term Level
Population Age: Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: DK (Completed) NO (Completed) FI (Completed) SE (Completed) HU (Completed) GB (Completed) DE (Completed) BE (Completed)
Trial results: View results
EudraCT Number: 2004-002889-38 Sponsor Protocol Number: OV-WV03 Start Date: 2004-12-16
Sponsor Name: OmniVision GmbH
Full Title: Randomisierte, kontrollierte, doppelblinde klinische Prüfung zur Untersuchung der Wirksamkeit und Verträglichkeit von Novesine® 0,4% Augentropfen im Vergleich zur Augentropfengrundlage bei zur Tono...
Medical condition:
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2004-002757-31 Sponsor Protocol Number: CLAF237A 2303E1 Start Date: 2004-12-16
Sponsor Name: Novartis Sverige AB
Full Title: A 28-Week Extension to a Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with LAF237 (50 mg qd or bid) to Placebo as Add-On Therapy in Patien...
Medical condition: Type 2 Dibetes
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Completed)
Trial results: View results
EudraCT Number: 2004-003962-14 Sponsor Protocol Number: BLO K022 Start Date: 2004-12-16
Sponsor Name: Takeda Pharma GmbH
Full Title: Candesartan "added" Treatment for Optimisation of Heart Failure (HF) Therapy - Effects on BNP and other HF associated Parameters. An open, non-controlled and multicentre trial
Medical condition: Heart failure
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2005-000492-18 Sponsor Protocol Number: 1050/04 Start Date: 2004-12-16
Sponsor Name: POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Full Title: Insulin resistance and endothelial dysfunction TNF-Alpha dependent in patients with rheumatoid arthritis or metabolic syndrome
Medical condition: Metabolic Syndrome and Rheumatoid Arthritis
Disease: Version SOC Term Classification Code Term Level
6.1 10021428 SOC
Population Age: Adults Gender: Male, Female
Trial protocol: IT (Completed)
Trial results: (No results available)
EudraCT Number: 2004-002940-82 Sponsor Protocol Number: CLAF237A2355 Start Date: 2004-12-16
Sponsor Name: Novartis Pharma Services AG
Full Title: A multicenter, randomized, double-blind, active controlled study to compare the effect of 24 weeks treatment with combination therapy of LAF237 and pioglitazone to LAF237 monotherapy or pioglitazon...
Medical condition: Type II Diabetes
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SK (Completed) CZ (Completed) GB (Completed) IT (Completed)
Trial results: View results

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe